[ad_1] LUND, Sweden, Oct. 26, 2018 / PRNewswire / – Hansa Medical AB (NASDAQ Stockholm: HMED), a leading biopharmaceutical company specializing in the inhibition of immunoglobulin G (IgG) mediated immunopathologies, has announced …
Read More »A presentation at ASN's Kidney Week in 2018 highlights stable renal function up to 24 months after transplantation, thanks to imlifidase | Business and Finance
